Headquartered in Wilmington, MA·Fiscal year ends December·NYSE: CRL·criver.com
About Charles River Laboratories
Charles River Laboratories International, Inc. (NYSE: CRL) is a contract research organization and supplier of essential products and services for pharmaceutical and biotechnology companies, government agencies and academic institutions engaged in drug discovery, early-stage development and safe manufacturing of new therapies.
It operates three reportable segments:
- **Discovery and Safety Assessment (DSA):** Its largest segment, providing regulated safety assessment (toxicology) studies and discovery services.
- **Manufacturing Solutions:** Includes Biologics Testing Solutions and Microbial Solutions, the latter featuring Endosafe endotoxin testing products.
- **Research Models and Services (RMS):** Supplies small and large research models and research model services such as Insourcing Solutions.
In May 2026 the company divested its CDMO and Cell Solutions businesses and certain European Discovery Services sites to sharpen its focus on regulated testing. It has also acquired the assets of a Cambodian non-human primate supplier and PathoQuest SAS.
Its current strategy centers on the Pathway to Purpose vision and the Create the Future efficiency initiative. It is also investing in digital platforms such as Apollo and in alternative, non-animal testing methods through its AMAP initiative. Updated
Charles River pulled 27.2% adjusted EPS growth out of a revenue base that still shrank, and raised its full-year revenue outlook above the Street. A firming read on pharma R&D demand.
Safety assessment demand is back: organic revenue in the Discovery and Safety Assessment unit grew 5.9%, enough for management to lift full-year non-GAAP EPS guidance to $11.35 to $11.55. Shedding the CDMO and Cell Solutions businesses shrank reported sales but pushed non-GAAP operating margin to 23.0%.
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising…
Pre-Market Stock Futures: Futures are trading mixed as we hit the midweek point, as the Space Exploration Technologies (NASDAQ: SPCX | SPCX Price Prediction) or SpaceX IPO rush is starting to fade…
Pre-Market Stock Futures: Futures are trading higher after yet another winning day for Wall Street, as all major indices finished the day higher after starting the session lower. Once again, all four…
Citi swept through its life science tools and diagnostics coverage on Wednesday, opening a 90-day upside catalyst watch on Agilent Technologies (NYSE:A | A Price Prediction) while trimming its price target on…
U.S. markets are on track for a slightly higher open Tuesday, but Tesla is struggling again after reporting December-quarter deliveries that fell short of expectations.
Friday’s top analyst upgrades and downgrades included America Movil, Ball, Ciena, Costco Wholesale, Dish Network, Fortinet, Infinera, Levi Strauss, Match, RingCentral, Robinhood Markets and Yum! Brands.
Friday's top analyst upgrades and downgrades included Annaly Capital Management, Carnival, Deere, Freeport-McMoRan, Honest Company, Royal Caribbean Cruises, Shoals Technologies, Take-Two Interactive Software, Toast and Yum China.
Friday's top analyst upgrades and downgrades included Altice USA, Applied Materials, Block, Coeur Mining, Consolidated Edison, Fastly, Shopify, SM Energy, Tata Motors and Wingstop.
Jefferies is out with its first top growth stock calls for 2021. These four top stock picks could be massive long-term winners, as they have significant catalysts that can drive growth for…
These four high-conviction health care stock ideas from the analysts at Jefferies all make sense for investors looking to gain exposure to a sector that should continue to do well the rest…
Wednesday's top analyst upgrades and downgrades included Bluebird Bio, Ciena, CommVault Systems, Dollar General, JD.com, Kroger, Nucor, Target and Walmart.
Charles River Laboratories International, Inc. (NYSE: CRL) is a contract research organization and supplier of essential products and services for pharmaceutical and biotechnology companies, government agencies and academic institutions engaged in drug discovery, early-stage development and safe manufacturing of new…
What is the CRL stock price target?
24/7 Wall St.'s 12-month price target for CRL is $387.70, rated Buy. The Wall Street consensus target is $346.07. CRL price prediction →
